|
In phase II trials, 90% of patients receiving dastinib showed normal blood
cell counts within six months. Of the 186 patients, 54% had been taking Gleevec
for more than three years and either failed to respond to the maximum dose or
developed drug-resistant versions of the disease.
Despite only a six-month follow up, a significant response to dasatinib was seen in all phases of the disease, says Dr. Andreas Hocchaus, a trial investigator at the University of Heidelberg in Germany. New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com CML (Chronic Myelogenous Leukemia Support List) --------------------------------- Part Of CMLHope.Com An International Community Of CML Patients For more information: http://cmlhope.com Post Message: [email protected] Subscribe: [EMAIL PROTECTED] Unsubscribe: [EMAIL PROTECTED] Change To No Mail/Web: [EMAIL PROTECTED] Change To Digest: [EMAIL PROTECTED] Change To Email: [EMAIL PROTECTED] List Help: [EMAIL PROTECTED] CML Group Web Site http://groups.yahoo.com/group/CML YAHOO! GROUPS LINKS
|
